Topic

Articles

NanoMab Technology has signed heads of terms with a supplier of Tungsten-188/Rhenium-188 generators, OncoBeta.

NanoMab Technology Signs Heads of Terms with OncoBeta

Recent data, from BIA and Clarivate, has revealed that investment in UK biotech continues to be strong.

UK Biotech Investment Continues to be Strong, According to Data

Optimus Holding has successfully completed the acquisition of OM Pharma.

Optimus Holding Successfully Completes Acquisition of OM Pharma

Jane E. Remillard is the leader of the Life Sciences Intellectual Property Team at Nelson Mullins, jane.remillard@nelsonmullins.com.

Jill Gorny Sloper is a partner at Nelson Mullins with a focus on patent law in the biotechnology, pharmaceutical, and life science fields, jill.sloper@nelsonmullins.com.

Stringent patentability requirements present a challenge to obtaining broad-based antibody claims, so companies should develop a strategy based on multiple reinforcing layers of protection. 

Patentability Considerations for Antibody-Related Inventions

Catalent has unveiled investment plans to create a European center of excellence for clinical biologics formulation development and drug product fill/finish services.

Catalent Invests Millions to Create European Clinical Manufacturing Center of Excellence

A strong immune response by patients receiving two doses of AZD1222 vaccine suggests a possible dosing strategy for COVID-19 vaccine.

AstraZeneca/Oxford Vaccine Shows Antibody and T-cell Responses

VAR2 Pharmaceuticals has been selected for its development of a drug-conjugated malaria protein that potentially selectively binds to most human tumor types.


VAR2 Pharmaceuticals Wins MilliporeSigma’s Advance Biotech Grant

The company now offers its CONFIDENCE virus clearance services to support validation of viral clearance processes.

Sartorius Stedim Biotech Launches Consultancy Services for Viral Clearance Validation

Citing clinical trial data that hydroxychloroquine did not show benefits for COVID-19 patients, FDA removes emergency use authorization for the drug as a treatment for the novel coronavirus. 

FDA Revokes EUA for Hydroxychloroquine

Novavax announces DoD contract to produce 10 million doses of COVID-19 vaccine candidate. 

Novavax Secures $60 Million in Government Funds

The companies have entered into a manufacturing agreement for the fill finish supply of lenzilumab for the potential treatment of COVID-19.

Ajinomoto Bio-Pharma Services, Humanigen in Manufacturing Agreement for COVID-19 Biologic

The acquisition gives Novovax an annual operating capacity of more that one billion doses of COVID-19 vaccine antigen.

Novavax Acquires Praha Vaccines, Expands Large-Scale Vaccine Manufacturing Capacity

Achieving herd immunity will require testing, data, a vaccine, and public support.

Are We All In This Together?

Working with incubators can provide cell and gene therapy developers with more opportunities. 

The Role of Incubators in Cell and Gene Therapy Development

This latest round of funding adds 14 new technology projects, workforce development, and Global Health Fund projects to NIIMBL's portfolio.

NIIMBL Funds Projects with $10 Million for Advances in Biopharma Manufacturing Innovation

Participants in two dosing cohorts in Moderna’s mRNA-1273 study reached or exceeded neutralizing antibody titers generally seen in convalescent sera.

mRNA Vaccine Shows Positive Interim Phase I Results

Catalent will manufacture a mRNA-based COVID-19 vaccine for clinical trials and potential commercialization.

Catalent, Arcturus Therapeutics Sign Vaccine Deal

FDA/FTC collaborate to end false and misleading statements and discuss the future of biosimilars at March 2020 public workshop on a competitive marketplace for biosimilars.

Commentary: A Competitive Marketplace for Biosimilars

FDA’s EUA provides the first new treatment for COVID-19 patients with severe symptoms.

BioBusiness